comprehensive -WSS

comprehensive

author：comprehensive 2025-09-04 04:25:51 - browse：294

Adam's take main illustration — Molly Ferguson/STAT

This week, an encouraging turnaround for Ocular Therapeutix, a chat with Alnylam’s CEO defending changes to the HELIOS-B study and talking up its hypertension treatment, and quick takes on Amylyx and obesity stocks.

A Worst CEO gets some much-needed help

For most of last year, Ocular Therapeutix CEO Antony Mattessich promised shareholders that he was close to nailing down a lucrative pharma partnership that would pay for late-stage clinical trials of the company’s treatments for degenerative eye diseases. The deal never happened. I heard from many Ocular investors who were frustrated and angry about Mattesich’s poor job performance. He ended up earning a spot last year on my worst biopharma CEO list. It was an easy pick.

On Thursday, Ocular announced a meaningful “leadership update.” Mattessich is still the CEO, but let’s just say the company’s board decided to surround him with new executives and retinal experts with proven track records of getting stuff done.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Bright Health sells Medicare Advantage business to Molina
Next article： Why are elite athletes different? Take a look at their microbes

WSS

Disclosing genetic information: not as worrisome as once feared

New guidelines on severe brain injury complicate already difficult decisions

Weight bias in eating disorder treatment complicated by new weight loss drugs

H5N1 communication has been strictly for the birds

Sanofi strikes deal with Novavax, boosting the vaccine maker

What nurses really want: sufficient staffing for patient care

Wikipedia

comprehensive

A Worst CEO gets some much-needed help

explore

Affirmative action in medical school literally saved lives

Gene therapy has helped boys walk. Can scientists keep it that way?

What does generative AI mean for health care? We asked experts

Why are elite athletes different? Take a look at their microbes

Continuity nursing helped my family in our darkest PICU moments

The science behind Janet Jackson's pregnancy at 49

Medicare details structure of new drug price negotiation program

FDA grants conditional OK to Sarepta’s gene therapy for Duchenne

The cancer drug shortage isn’t new — and neither are the solutions

WATCH: Why do fingernails fall off when they're damaged?

hotspot

Elevance, private equity launch primary care company

Ask STAT: What do you want to know about ChatGPT in medicine?

It shouldn't be easy to buy synthetic DNA to recreate a deadly virus

What would happen to your eyes if you looked at the solar eclipse?

After gene therapy, two congenitally deaf children hear for the first time

Study: Lilly Alzheimer's therapy slowed patients' cognitive decline

hotspot

Wikipedia

focus

explore